This Funding Opportunity Announcement (FOA) encourages research to enable the optimal adaptation, introduction, and placement of effective, affordable, and quality-assured innovative diagnostic solutions for tuberculosis (TB) detection that consider the integration, complementarity, and fit within the current diagnostic context in high burden countries and the linkages to care in response to the needs of affected communities. For this call, diagnostic solutions refer to diagnostic and detection devices and platforms which could include multi-disease testing platforms, digital technologies used for contact tracing and diagnosis, CAD-enabled technology, and sample collection tools and handling. In addition, solutions with demonstrated innovation and impact in response to COVID-19 or other relevant disease areas are included. Any solution proposed should have superior performance compared to currently available tools and/or enable TB detection at the point of care.
 
Applicants are encouraged to consider products that are available on the market or can be introduced in the market by no later than December 2022.
 
Support is available for up to 5 years. Unitaid anticipates funding 2-3 projects at $20-30 million.
 
eRA Finance Approver deadline: Wednesday, 12 May 2021
RC&I deadline: Monday, 17 May 2021
Funder due date: Monday, 24 May 2021 at 12:00 (SAST)

Click here for more information. 

Cellular and Molecular Biology of Complex Brain Disorders (R21) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. The R21 activity code can be used for applications to develop early stage, high-risk, exploratory or proof-of-concept approaches where there is little or no preliminary data.

Grants are available for up to two years. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
 
eRA Finance Approver deadline: Thursday, 3 June 2021
RC&I deadline: Tuesday, 8 June 2021
NIH due date: Wednesday, 16 June 2021 at 17:00 (SAST) (note this is a public holiday in South Africa)
 
Further detail for this opportunity can be found here.
 
Please complete this FHS intention-to-submit form by 23 April 2021 if you intend applying for this call. Please note that completion of this form is for the purposes of internal support and tracking, it is not linked to funder application processes and does not commit you to applying to this opportunity.

The International Bioethics Research Training program (D43) supports mentored doctoral and long-term postdoctoral research training for ethics experts from low- and middle-income countries (LMICs) that complements other global health research and research training programs in the mission areas of the NIH Institutes and Centers.
 
Grants of $230,000 direct costs per year are available for up to five years.
 
eRA Finance Approver deadline: Tuesday, 25 May 2021
RC&I deadline: Friday, 28 May 2021
NIH due date: Friday, 4 June 2021 by 17:00 (SAST)
 
Further detail for this opportunity can be found here. 
 
Please complete this intention-to-submit form by 23 April 2021 if you intend applying for this call. Please note that completion of this form is for the purposes of internal support and tracking, it is not linked to funder application processes and does not commit you to applying to this opportunity.

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01) funding opportunity encourages the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications).
 
Grants are available for up to five years and applicants may request up to $475,000 in direct costs per year.
 
eRA Finance Approver deadline: Friday, 21 May 2021
RC&I deadline: Wednesday, 26 May 2021
NIH due date: Wednesday, 2 June 2021 at 17:00 (SAST)
 
Further detail for this opportunity can be found here.
 
Please complete this FHS intention-to-submit form by 28 April 2021 if you intend applying for this call. Please note that completion of this form is for the purposes of internal support and tracking, it is not linked to funder application processes and does not commit you to applying to this opportunity.